Please wait while the formulary information is being retrieved.
SUPPRELIN LA (HISTRELIN ACETATE)
- Precocious puberty
50 mg (65 mcg/day) implant kit
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- None
- Pregnancy
Contraindicated
- Depression
- Suicidal ideation
Severe
Moderate
- Seizure disorder
SUPPRELIN LA (HISTRELIN ACETATE)
- Precocious puberty
- None
- Headache disorder
- Injection site sequelae
- Localized edema
More Frequent
Severe
Less Severe
- Behavioral disorders
- Depression
- Hypersensitivity drug reaction
- Epistaxis
- Keratoderma
- Mastalgia
- Pruritus of skin
- Scar of skin
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Breakage of implant
- Seizure disorder
- Suicidal ideation
Less Severe
- Abnormal vaginal bleeding
- Aggressive behavior
- Dysmenorrhea
- Erythema
- Gynecomastia
- Irritability
- Mood changes
- Sensation of cold
Contraindicated
None
Severe Precaution
Histrelin
No safety and efficacy age < 2 years. Not recommended.
- 1 Day – 2 Years
- No safety and efficacy age < 2 years. Not recommended.
Management or Monitoring Precaution
None
Histrelin
- Severity Level:
1
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Histrelin
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Precocious puberty | |
| E30.1 | Precocious puberty |
| 0-9 | A-Z |
|---|---|
| E30.1 | Precocious puberty |
Formulary Reference Tool